Submit a comment

Inhibition of experimental asthma by indoleamine 2,3-dioxygenase
Tomoko Hayashi, Lucinda Beck, Cyprian Rossetto, Xing Gong, Osamu Takikawa, Kenji Takabayashi, David H. Broide, Dennis A. Carson, Eyal Raz
Tomoko Hayashi, Lucinda Beck, Cyprian Rossetto, Xing Gong, Osamu Takikawa, Kenji Takabayashi, David H. Broide, Dennis A. Carson, Eyal Raz
View: Text | PDF
Article Immunology

Inhibition of experimental asthma by indoleamine 2,3-dioxygenase

Abstract

Epidemiological evidence points to the inverse relationship between microbial exposure and the prevalence of allergic asthma and autoimmune diseases in Westernized countries. The molecular basis for this observation has not yet been completely delineated. Here we report that the administration of certain toll-like receptor (TLR) ligands, via the activation of innate immunity, induces high levels of indoleamine 2,3-dioxygenase (IDO), the rate-limiting enzyme of tryptophan catabolism in various organs. TLR9 ligand–induced pulmonary IDO activity inhibits Th2-driven experimental asthma. IDO activity expressed by resident lung cells rather than by pulmonary DCs suppressed lung inflammation and airway hyperreactivity. Our results provide a mechanistic insight into the various formulations of the hygiene hypothesis and underscore the notion that activation of innate immunity can inhibit adaptive Th cell responses.

Authors

Tomoko Hayashi, Lucinda Beck, Cyprian Rossetto, Xing Gong, Osamu Takikawa, Kenji Takabayashi, David H. Broide, Dennis A. Carson, Eyal Raz

×

Guidelines

The Editorial Board will only consider comments that are deemed relevant and of interest to readers. The Journal will not post data that have not been subjected to peer review; or a comment that is essentially a reiteration of another comment.

  • Comments appear on the Journal’s website and are linked from the original article’s web page.
  • Authors are notified by email if their comments are posted.
  • The Journal reserves the right to edit comments for length and clarity.
  • No appeals will be considered.
  • Comments are not indexed in PubMed.

Specific requirements

  • Maximum length, 400 words
  • Entered as plain text or HTML
  • Author’s name and email address, to be posted with the comment
  • Declaration of all potential conflicts of interest (even if these are not ultimately posted); see the Journal’s conflict-of-interest policy
  • Comments may not include figures
This field is required
This field is required
This field is required
This field is required
This field is required
This field is required